Last reviewed 2026-05-27 · How we verify

Tricyclamol Methochloride (TRICYCLAMOL CHLORIDE)

Phase 2 active Small molecule

Tricyclamol Methochloride (generic name: TRICYCLAMOL CHLORIDE) is a drug. It is currently in Phase 2 development.

Tricyclamol Methochloride is a small molecule that works by interacting with specific biological molecules, but the exact mechanism is unknown.

Tricyclamol Methochloride, also known as Tricyclamol Chloride, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological molecules, but the exact mechanism is unknown. Further research is needed to understand its potential therapeutic applications and safety profile.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	TRICYCLAMOL CHLORIDE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a city, and Tricyclamol Methochloride is a key that unlocks a specific door to change how the city works. However, since the target and mechanism of action are unknown, it's like trying to find the right key without knowing what door it unlocks. More research is needed to understand how it works and what it does.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tricyclamol Methochloride CI brief — competitive landscape report
Tricyclamol Methochloride updates RSS · CI watch RSS

Frequently asked questions about Tricyclamol Methochloride

What is Tricyclamol Methochloride?

Tricyclamol Methochloride (TRICYCLAMOL CHLORIDE) is a Small molecule drug.

How does Tricyclamol Methochloride work?

Tricyclamol Methochloride is a small molecule that works by interacting with specific biological molecules, but the exact mechanism is unknown.

What is the generic name of Tricyclamol Methochloride?

TRICYCLAMOL CHLORIDE is the generic (nonproprietary) name of Tricyclamol Methochloride.

What development phase is Tricyclamol Methochloride in?

Tricyclamol Methochloride is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing